TWI860993B - 唑化合物晶體 - Google Patents

唑化合物晶體 Download PDF

Info

Publication number
TWI860993B
TWI860993B TW108111946A TW108111946A TWI860993B TW I860993 B TWI860993 B TW I860993B TW 108111946 A TW108111946 A TW 108111946A TW 108111946 A TW108111946 A TW 108111946A TW I860993 B TWI860993 B TW I860993B
Authority
TW
Taiwan
Prior art keywords
crystal
crystals
ointment
infrared absorption
compound
Prior art date
Application number
TW108111946A
Other languages
English (en)
Chinese (zh)
Other versions
TW202012380A (zh
Inventor
彥
安富貴之
廣田良輔
Original Assignee
日商大塚製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商大塚製藥股份有限公司 filed Critical 日商大塚製藥股份有限公司
Publication of TW202012380A publication Critical patent/TW202012380A/zh
Application granted granted Critical
Publication of TWI860993B publication Critical patent/TWI860993B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW108111946A 2018-04-04 2019-04-03 唑化合物晶體 TWI860993B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018072717 2018-04-04
JP2018-072717 2018-04-04

Publications (2)

Publication Number Publication Date
TW202012380A TW202012380A (zh) 2020-04-01
TWI860993B true TWI860993B (zh) 2024-11-11

Family

ID=66223774

Family Applications (2)

Application Number Title Priority Date Filing Date
TW108111946A TWI860993B (zh) 2018-04-04 2019-04-03 唑化合物晶體
TW113146840A TW202515853A (zh) 2018-04-04 2019-04-03 㗁唑化合物晶體

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113146840A TW202515853A (zh) 2018-04-04 2019-04-03 㗁唑化合物晶體

Country Status (26)

Country Link
US (4) US11414391B2 (cg-RX-API-DMAC7.html)
EP (2) EP4400167A3 (cg-RX-API-DMAC7.html)
JP (4) JP7326295B2 (cg-RX-API-DMAC7.html)
KR (2) KR102764726B1 (cg-RX-API-DMAC7.html)
CN (1) CN111902402B (cg-RX-API-DMAC7.html)
AU (2) AU2019249562B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020019377A2 (cg-RX-API-DMAC7.html)
CA (1) CA3095866A1 (cg-RX-API-DMAC7.html)
DK (1) DK3774745T3 (cg-RX-API-DMAC7.html)
EA (1) EA202092393A1 (cg-RX-API-DMAC7.html)
ES (1) ES2982586T3 (cg-RX-API-DMAC7.html)
FI (1) FI3774745T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240858T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066793T2 (cg-RX-API-DMAC7.html)
IL (2) IL315425A (cg-RX-API-DMAC7.html)
LT (1) LT3774745T (cg-RX-API-DMAC7.html)
MX (1) MX2020010435A (cg-RX-API-DMAC7.html)
MY (1) MY202406A (cg-RX-API-DMAC7.html)
PH (1) PH12020551605A1 (cg-RX-API-DMAC7.html)
PL (1) PL3774745T3 (cg-RX-API-DMAC7.html)
PT (1) PT3774745T (cg-RX-API-DMAC7.html)
SG (1) SG11202009564TA (cg-RX-API-DMAC7.html)
SI (1) SI3774745T1 (cg-RX-API-DMAC7.html)
TW (2) TWI860993B (cg-RX-API-DMAC7.html)
WO (1) WO2019194211A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006134B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3774745T3 (pl) * 2018-04-04 2024-08-19 Otsuka Pharmaceutical Co., Ltd. Kryształ cząsteczki oksazolu
EP4501324A4 (en) 2022-03-25 2026-04-08 Otsuka Pharma Co Ltd WOUND TREATMENT COMPOSITION
CN115887463A (zh) * 2022-12-27 2023-04-04 瑞石生物医药有限公司 一种含环酰胺化合物的药物组合物
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
US20260076788A1 (en) * 2024-09-17 2026-03-19 Natalie DeVoir Orthodontic composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017115780A1 (en) * 2015-12-28 2017-07-06 Otsuka Pharmaceutical Co., Ltd. Ointment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI330639B (en) * 2005-11-15 2010-09-21 Otsuka Pharma Co Ltd Oxazole compound and pharmaceutical composition
EP2890686B1 (en) * 2012-08-30 2017-01-04 Otsuka Pharmaceutical Co., Ltd. Method for producing oxazole compound
PL3774745T3 (pl) * 2018-04-04 2024-08-19 Otsuka Pharmaceutical Co., Ltd. Kryształ cząsteczki oksazolu

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017115780A1 (en) * 2015-12-28 2017-07-06 Otsuka Pharmaceutical Co., Ltd. Ointment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 张奇, 梅雪锋. 固体药物的转晶现象 药学学报 2015, 50(5) 药学学报 2015年, 521-527, *

Also Published As

Publication number Publication date
AU2019249562B2 (en) 2024-06-27
AU2024220015A1 (en) 2024-10-17
MX2020010435A (es) 2020-10-28
CA3095866A1 (en) 2019-10-10
IL277730B1 (en) 2024-10-01
IL315425A (en) 2024-11-01
JP2024001115A (ja) 2024-01-09
WO2019194211A1 (en) 2019-10-10
TW202012380A (zh) 2020-04-01
EP4400167A2 (en) 2024-07-17
US20250250243A1 (en) 2025-08-07
EP3774745B1 (en) 2024-05-29
EP3774745A1 (en) 2021-02-17
ZA202006134B (en) 2023-03-29
IL277730B2 (en) 2025-02-01
AU2019249562A1 (en) 2020-10-22
KR20250022254A (ko) 2025-02-14
US20210147370A1 (en) 2021-05-20
JP2021517111A (ja) 2021-07-15
PH12020551605A1 (en) 2021-04-26
TW202515853A (zh) 2025-04-16
JP7326295B2 (ja) 2023-08-15
LT3774745T (lt) 2024-07-10
CN111902402A (zh) 2020-11-06
JP2025128238A (ja) 2025-09-02
SI3774745T1 (sl) 2024-08-30
US20240076275A1 (en) 2024-03-07
IL277730A (en) 2020-11-30
JP2022037040A (ja) 2022-03-08
BR112020019377A2 (pt) 2021-01-05
CN111902402B (zh) 2026-07-14
SG11202009564TA (en) 2020-10-29
HRP20240858T1 (hr) 2024-10-11
FI3774745T3 (fi) 2024-06-19
PL3774745T3 (pl) 2024-08-19
ES2982586T3 (es) 2024-10-16
US11840512B2 (en) 2023-12-12
EP4400167A3 (en) 2024-09-25
US20220411386A1 (en) 2022-12-29
PT3774745T (pt) 2024-06-25
HUE066793T2 (hu) 2024-09-28
EA202092393A1 (ru) 2021-01-25
US11414391B2 (en) 2022-08-16
MY202406A (en) 2024-04-27
KR102764726B1 (ko) 2025-02-11
AU2024220015B2 (en) 2026-03-26
DK3774745T3 (da) 2024-06-17
KR20200139736A (ko) 2020-12-14

Similar Documents

Publication Publication Date Title
TWI597277B (zh) 一種酪胺酸激酶抑制劑的二馬來酸鹽的第i型結晶及製備方法
JP2024001115A (ja) オキサゾール化合物結晶
JP2025114691A (ja) オキサゾール化合物結晶
JP4657393B2 (ja) ドキサゾシン・メシレートの新規な形態iii
TWI708764B (zh) 一種雄性激素受體抑制劑的結晶形式及其製備方法
HK40040843A (en) Oxazole compound crystal
HK40113056A (en) Oxazole compound crystal
JP7689778B2 (ja) ペプチドボロン酸系化合物の新規な結晶形およびその調製方法
HK40036102B (en) Oxazole compound crystal
HK40036102A (en) Oxazole compound crystal
EA042645B1 (ru) Кристаллическое соединение оксазола
HK1199027B (en) Crystalline form i of tyrosine kinase inhibitor dimaleate and preparation methods thereof
CN105473547A (zh) 阿戈美拉汀和磺酸的新复合物、其制备方法和包含其的药物组合物